(A.C. Kentner).
Animal models of maternal immune activation (mIA) have emerged as both translationally relevant and essential for targeting the molecular mechanisms underlying neuropsychiatric disorders (Estes and McAllister, 2016; Knuesel et al., 2014; Kentner et al., 2018; Gumusoglu and Stevens, 2018) . Importantly, experimental outcomes associated with mIA vary as a function of specific study components (e.g. immunogen, dose, species/strain) and other husbandry considerations that are typically under reported yet influential to the immune response and the integrity of our animal models (Estes and McAllister, 2016; Kentner et al., 2018) . In this issue of Brain, Behavior, and Immunity, Murray et al. (2018) lay groundwork to guide the establishment of best practices for the validation and reporting of our mIA models. These steps built the foundation from which their laboratory explored the early developmental trajectory of morphometric markers in male and female offspring, revealing sexually dimorphic phenotypic changes following mIA.
Across the past decade there has been a growing consciousness calling for increased scientific rigor and reproducibility (Collins and Tabak, 2014) , and for better reporting standards (Kilkenny et al., 2010) in biomedical research. Within this context, Murray et al. (2018) astutely identified issues in the mIA literature including a lack of defined criteria for how important elements of our study protocols are selected. For example, the immunogens and doses of interest, administration routes and schedules, in addition to the specific strains and sex employed. While this list is not exhaustive, these are fundamental components to every mIA study and the rationale for our choices ought to be transparent and evidence-based. The importance of this is highlighted by Murray et al. (2018) who point out that while mice are most commonly used in the mIA literature, the use of rats is increasing too. Although some mIA mouse models have been validated, the same methods may not be appropriate for other species and further validation of these models are necessary.
Beyond the issue of species comparisons, basic husbandry differences between laboratories (e.g. ventilation systems) may lead to large variations in the efficacy of mIA models to induce long-term programming effects (Mueller et al., 2018) . Each laboratory must now take an initiative to parse out and validate the appropriate conditions under which they effectively induce their mIA models, and duly report (Kentner et al., 2018) . As an excellent template of how to go about this, Murray et al. (2018) evaluated the pharmacodynamic properties of the peripheral immune response, as activated by polyriboinosinicpolyribocytidylic acid (poly I:C), in three strains of female rats. The investigators focused on plasma interleukin (IL)-6 concentration and body temperature to confirm a mIA response. The optimal dosing schedule and animal strain were then selected based on a predefined set of criteria for identifying what best worked under their particular laboratory conditions. In this case, the choice was rationalized based on the variability of the mIA response between strains and doses. Moreover, these preliminary data were reported as evidence for the methodology chosen.
Although it may have been preferable to validate the administration schedule with pregnant dams, the investigators used virgin females in
